Treatment of Fibrosing Mediastinitis in Pulmonary Hypertension

This protocol targets the specific clinical scenario of pulmonary hypertension caused by fibrosing mediastinitis — a distinct and challenging subset that requires careful therapeutic consideration.

Clinical Situation

When pulmonary hypertension develops in the context of fibrosing mediastinitis, the vascular and hemodynamic profile of this patient population introduces significant complexity for any treatment decision.

Treatment Approach (Partial)

The reported strategy involves an off-label vasodilatory approach — applied with substantial caution in light of the hemodynamic complexities specific to this setting.

Selection criteria, complete agent choices, and sequencing are detailed in the full structured regimen below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1007/s13665-025-00382-3

In patients with pulmonary hypertension, it has been reported that pulmonary vasodilators have been used as off-label therapies but would caution the use given the vascular and hemodynamic complexities in this patient population.

View source ↗